Who is sponsoring NCT04560881?

NCT04560881 is sponsored by Laboratorio Elea Phoenix S.A..

What drugs are being tested in NCT04560881?

Interventions in NCT04560881: Inactivated SARS-CoV-2 vaccine (Vero cell), Placebo/Aluminum Adjuvant of Inactivated SARS-CoV-2 vaccine.

What condition does NCT04560881 study?

NCT04560881 studies COVID-19 Virus Infection.

Is NCT04560881 still recruiting?

NCT04560881 is currently completed. Last updated 12 January 2022.

Last reviewed 2022-01-12 · How we verify

NCT04560881

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Clinical Trial to Evaluate the Efficacy, Immunogenicity and Safety of the Inactivated SARS-CoV-2 Vaccine (COVID-19)

Completed Phase 3 Last updated 12 January 2022

What this trial tests

Phase 3 trial testing Inactivated SARS-CoV-2 vaccine (Vero cell) in COVID-19 Virus Infection in 3,000 participants. Completed in 13 December 2021.

Timeline

16 September 2020

Primary endpoint
13 December 2021

13 December 2021

Quick facts

Lead sponsor	Laboratorio Elea Phoenix S.A.
Phase	Phase 3
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	triple
Primary purpose	prevention
Enrollment	3,000
Start date	16 September 2020
Primary completion	13 December 2021
Estimated completion	13 December 2021
Sites	4 locations across Argentina

Drugs / interventions tested

Inactivated SARS-CoV-2 vaccine (Vero cell)
Placebo/Aluminum Adjuvant of Inactivated SARS-CoV-2 vaccine — full drug profile →

Conditions studied

COVID-19 Virus Infection — all drugs for COVID-19 Virus Infection →

Sponsor

Laboratorio Elea Phoenix S.A. — full company profile →

Who can join

Adults 18 to 85, any sex, with COVID-19 Virus Infection. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a randomized, double blind, placebo parallel-controlled phase III clinical trial to evaluate the efficacy, immunogenicity and safety of the inactivated SARS-CoV-2 Vaccine (Vero cell) in Argentine healthy population aged between 18 and 85 years old.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Viral targets for vaccines against COVID-19.
Dai L, Gao GF. · · 2021 · cited 836× · PMID 33340022 · DOI 10.1038/s41577-020-00480-0
SARS-CoV-2 vaccines strategies: a comprehensive review of phase 3 candidates.
Kyriakidis NC, López-Cortés A, González EV, Grimaldos AB, et al · · 2021 · cited 507× · PMID 33619260 · DOI 10.1038/s41541-021-00292-w
Coronavirus vaccine development: from SARS and MERS to COVID-19.
Li YD, Chi WY, Su JH, Ferrall L, et al · · 2020 · cited 242× · PMID 33341119 · DOI 10.1186/s12929-020-00695-2
COVID-19 vaccines: rapid development, implications, challenges and future prospects.
Kashte S, Gulbake A, El-Amin Iii SF, Gupta A. · · 2021 · cited 240× · PMID 33677814 · DOI 10.1007/s13577-021-00512-4
Efficacy and safety of COVID-19 vaccines.
Graña C, Ghosn L, Evrenoglou T, Jarde A, et al · · 2022 · cited 227× · PMID 36473651 · DOI 10.1002/14651858.cd015477
A Comprehensive Review of the Global Efforts on COVID-19 Vaccine Development.
Li Y, Tenchov R, Smoot J, Liu C, et al · · 2021 · cited 215× · PMID 34056083 · DOI 10.1021/acscentsci.1c00120
COVID-19 vaccine: A recent update in pipeline vaccines, their design and development strategies.
Rawat K, Kumari P, Saha L. · · 2021 · cited 169× · PMID 33245898 · DOI 10.1016/j.ejphar.2020.173751
COVID-19: A review of therapeutic strategies and vaccine candidates.
Izda V, Jeffries MA, Sawalha AH. · · 2021 · cited 159× · PMID 33217545 · DOI 10.1016/j.clim.2020.108634

Verify or expand the search:

Other Laboratorio Elea Phoenix S.A. trials

Trials by the same sponsor.

NCT04897516 — Shorter Benznidazole Regimens Compared to the Standard Regimen for Chagas Disease · Phase 3 · recruiting
NCT04355936 — Telmisartan for Treatment of COVID-19 Patients · Phase 4 · completed
NCT04381884 — Ivermectin Effect on SARS-CoV-2 Replication in Patients With COVID-19 · Phase 2 · completed
NCT03317236 — Bioequivalence Study of Two Extended Release Formulations Containing 50 mg of Quetiapine. · Phase 4 · completed
NCT03668054 — Safety and Clinical Effectiveness of Intravitreal Bevacizumab (Lumiere®) in Patients With Wet Age-related Macular Degene · Phase 3 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04560881 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Laboratorio Elea Phoenix S.A.
Last refreshed: 12 January 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04560881.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing